BioCorRx Acquires LUCEMYRA: A Strategic Move in Opioid Withdrawal Treatment

BioCorRx Pharmaceuticals Inc. has acquired LUCEMYRA (lofexidine), a groundbreaking FDA-approved prescription medication designed to mitigate opioid withdrawal symptoms. This strategic acquisition represents a significant milestone in the company's mission to provide innovative, non-opioid treatment solutions for substance abuse disorders.

LUCEMYRA stands out as the first and only non-opioid medication approved by the FDA specifically to address opioid withdrawal symptoms. The medication works by reducing norepinephrine release, which helps suppress the neurochemical surge that produces acute withdrawal symptoms. Clinical trials have demonstrated its effectiveness in reducing the severity of withdrawal experiences compared to placebo.

The acquisition comes at a critical time in the ongoing opioid crisis, where innovative treatment options are desperately needed. By integrating LUCEMYRA into its product portfolio, BioCorRx Pharmaceuticals aims to improve access to withdrawal treatment and provide a critical solution for patients experiencing opioid discontinuation.

Under the agreement's terms, USWM, LLC will retain a portion of future sales and receive shares of common stock and warrants from BioCorRx Inc. The company projects LUCEMYRA will generate meaningful sales and serve as a key asset in its expanding product line.

Lourdes Felix, CEO of BioCorRx, emphasized the strategic importance of this acquisition, noting that it aligns with the company's commitment to combating the opioid crisis. By leveraging their expertise in behavioral health and extensive network of treatment centers, BioCorRx plans to expand LUCEMYRA's market presence and improve treatment accessibility.

The medication is administered orally for up to 14 days, with dosing guided by withdrawal symptoms. While LUCEMYRA does not completely prevent withdrawal symptoms, it provides significant relief for patients undergoing opioid detoxification. Potential side effects include orthostatic hypotension, bradycardia, dizziness, and dry mouth.

This acquisition represents more than a business transaction; it signifies a potential breakthrough in addressing one of the most challenging aspects of substance use disorder treatment. By offering a non-opioid solution for managing withdrawal symptoms, BioCorRx Pharmaceuticals is contributing to a more comprehensive and compassionate approach to addiction recovery.